CATEGORIZATION OF WILMS TUMOR BY GENETIC EXPRESSION

根据基因表达对肾母细胞瘤进行分类

基本信息

项目摘要

DESCRIPTION: (Applicant's Description) Wilms tumor represents the most common renal neoplasm of childhood. Remarkable success has been achieved in the therapy of WT through the National Wilms Tumor Study Group (NWTS). Despite the responsiveness of most WT to adjuvant chemotherapy, some tumors are unresponsive and result in tumor progression and death. Most tumors lack distinctive histologic or clinical features to enable targeting with more or less aggressive chemotherapy. Recognizing biologically distinctive subsets of WT may be useful for predicting clinical behavior and targeting therapy. The goal of this project is to identify molecular categories of WT that have predictable clinical properties, including propensity to metastasize and response to therapy. We hypothesize that gene expression profiles will aid in the recognition of these categories. AIM ONE: To identify candidate marker genes that are differentially expressed: Using commercially available cDNA macro-arrays, we will comprehensively analyze gene expression in a small group of Wilms tumors. A subset of genes whose expression varies throughout these tumors will be identified. AIM TWO: To identify molecular categories of Wilms tumor based upon the expression of candidate marker genes identified in Aim One: Utilizing custom cDNA microarrays approximately 200-300 pathologically, clinically and genetically characterized WT will be analyzed. Using computationally assisted methods, profiles of gene expression that define molecular categories of Wilms tumors will be identified. AIM THREE: To verify, test, and model the new molecular categories of Wilms tumor and to examine these new categories in their clinical, pathologic, and genetic context. Each molecular category will be analyzed and validated for clinical, pathologic and genetic features using the extensive resources of the NWTS. Genes predictive of molecular categories will be verified using in situ hybridization or immunohistochemistry. A model categorization will be proposed and tested on 200 additional Wilms tumors.
描述:(申请人描述)肾母细胞瘤是最常见的肿瘤

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Elizabeth J Perlman其他文献

Elizabeth J Perlman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Elizabeth J Perlman', 18)}}的其他基金

Epigenetic and clinical impact of SMARCB1 loss in cancer
SMARCB1 缺失对癌症的表观遗传学和临床影响
  • 批准号:
    8495294
  • 财政年份:
    2012
  • 资助金额:
    $ 25.81万
  • 项目类别:
Epigenetic and clinical impact of SMARCB1 loss in cancer
SMARCB1 缺失对癌症的表观遗传学和临床影响
  • 批准号:
    8386397
  • 财政年份:
    2012
  • 资助金额:
    $ 25.81万
  • 项目类别:
Validation of copy number changes by MLPA as predictors of relapse in Wilms tumor
验证 MLPA 的拷贝数变化作为肾母细胞瘤复发的预测因素
  • 批准号:
    8330806
  • 财政年份:
    2011
  • 资助金额:
    $ 25.81万
  • 项目类别:
Validation of copy number changes by MLPA as predictors of relapse in Wilms tumor
验证 MLPA 的拷贝数变化作为肾母细胞瘤复发的预测因素
  • 批准号:
    8028602
  • 财政年份:
    2011
  • 资助金额:
    $ 25.81万
  • 项目类别:
CATEGORIZATION OF WILMS TUMOR BY GENETIC EXPRESSION
根据基因表达对肾母细胞瘤进行分类
  • 批准号:
    6693352
  • 财政年份:
    2001
  • 资助金额:
    $ 25.81万
  • 项目类别:
CATEGORIZATION OF WILMS TUMOR BY GENETIC EXPRESSION
根据基因表达对肾母细胞瘤进行分类
  • 批准号:
    6196587
  • 财政年份:
    2001
  • 资助金额:
    $ 25.81万
  • 项目类别:
CATEGORIZATION OF WILMS TUMOR BY GENETIC EXPRESSION
根据基因表达对肾母细胞瘤进行分类
  • 批准号:
    6837672
  • 财政年份:
    2001
  • 资助金额:
    $ 25.81万
  • 项目类别:
CATEGORIZATION OF WILMS TUMOR BY GENETIC EXPRESSION
根据基因表达对肾母细胞瘤进行分类
  • 批准号:
    6553456
  • 财政年份:
    2001
  • 资助金额:
    $ 25.81万
  • 项目类别:
CATEGORIZATION OF WILMS TUMOR BY GENETIC EXPRESSION
根据基因表达对肾母细胞瘤进行分类
  • 批准号:
    7017074
  • 财政年份:
    2001
  • 资助金额:
    $ 25.81万
  • 项目类别:

相似海外基金

FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
  • 批准号:
    EP/Y036395/1
  • 财政年份:
    2024
  • 资助金额:
    $ 25.81万
  • 项目类别:
    Research Grant
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
  • 批准号:
    10715568
  • 财政年份:
    2023
  • 资助金额:
    $ 25.81万
  • 项目类别:
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
  • 批准号:
    10764456
  • 财政年份:
    2023
  • 资助金额:
    $ 25.81万
  • 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
  • 批准号:
    10743328
  • 财政年份:
    2023
  • 资助金额:
    $ 25.81万
  • 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
  • 批准号:
    10638813
  • 财政年份:
    2023
  • 资助金额:
    $ 25.81万
  • 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
  • 批准号:
    10828665
  • 财政年份:
    2023
  • 资助金额:
    $ 25.81万
  • 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
  • 批准号:
    10823828
  • 财政年份:
    2023
  • 资助金额:
    $ 25.81万
  • 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
  • 批准号:
    10721095
  • 财政年份:
    2023
  • 资助金额:
    $ 25.81万
  • 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
  • 批准号:
    10795328
  • 财政年份:
    2023
  • 资助金额:
    $ 25.81万
  • 项目类别:
Clinical Research and Academic Success in Obstetrics & Gynecology
产科临床研究和学术成就
  • 批准号:
    10828252
  • 财政年份:
    2023
  • 资助金额:
    $ 25.81万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了